Global Hematopoietic Stem Cell Transplantation Market Size 2024, Forecast To 2033
6 Mar, 2024
The hematopoietic stem cell transplantation market has also demonstrated robust growth, starting from $4.24 billion in 2023 and climbing to $4.65 billion in 2024 at a CAGR of 9.6%. The historic period's growth can be attributed to early transplantation techniques, limited indications and donor sources, advancements in conditioning regimens, and the emergence of allogeneic transplants, alongside regulatory milestones. Looking ahead, this market is projected to experience rapid expansion, reaching $6.82 billion in 2028 with a CAGR of 10.1%. The forecast period's growth is expected to be driven by expanded treatment indications, donor source diversification, personalized medicine and genomics, regulatory changes and guidelines, and market expansion and accessibility.
Global Hematopoietic Stem Cell Transplantation Market Key Driver
The increased frequency of blood cancer is expected to propel the growth of the hematopoietic stem cell transplantation market. A group of malignancies that impact the development and operation of blood cells are referred to as blood cancers. Leukemia, lymphoma, and myeloma are the three main types of blood cancer. By replacing stem cells and bone marrow cells that have been killed by the malignancy, hematopoietic stem cell transplantation is generally used to treat blood cancer. These new stem cells can then move to the bone marrow and start creating new blood cells. So, these factors boost the hematopoietic stem cell transplantation market. For instance, in August 2022, according to the report shared by Blood Cancer UK, a UK-based non-profit organization, there are 41,000 blood cancer cases identified each year, making blood cancer the sixth most prevalent malignancy in the UK. Blood cancer, which affects one in 16 men and one in 22 women at some time in their lives, will afflict around 250,000 people in the UK in 2022. Additionally, more than 500 children under the age of 15 are affected by blood cancer each year. 400 of them have pediatric leukemia, and 100 of them have lymphoma. Therefore, the increased frequency of blood cancer drives the hematopoietic stem cell transplantation market. By 2024, the hematopoietic stem cell transplantation market is expected to witness substantial growth due to the rising incidence of blood cancer cases.
Get A Free Sample Of The Global Hematopoietic Stem Cell Transplantation Market ReportGlobal Hematopoietic Stem Cell Transplantation Market Segments
The hematopoietic stem cell transplantation market covered in this report is segmented –
1) By Type: Allogeneic, Autologous
2) By Indication: Leukemia, Lymphatic Disorder, Myeloma, Other Non-Malignant Disorders
3) By Application: Bone Marrow Transplant, Peripheral Blood Stem Cell Transplant, Cord Blood Transplant
4) By End User: Hospital Pharmacy, Retail Pharmacy, Specialty Clinics
By Geography:The regions covered in the hematopoietic stem cell transplantation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the hematopoietic stem cell transplantation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global hematopoietic stem cell transplantation market during the forecast period. The regions covered in the hematopoietic stem cell transplantation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Hematopoietic Stem Cell Transplantation Industry Players
Pluristem Therapeutics Inc., Lonza Group AG, Escape Therapeutics Inc., Regen Biopharma Inc., Bluebird Bio Inc., CellGenix GmbH, CBR Systems Inc., Merck KGaA, Cord Blood Corporation, Kiadis Pharma NV, Marker Therapeutics Inc., Taiga Biotechnologies Inc., Takeda Pharmaceutical Company Limited, Talaris Therapeutics Inc., ViaCord LLC, ScienCell Research Laboratories Inc., BiolineRx, Stemcell Technologies Inc., ThermoGenesis Holdings Inc., MEDIPOST Co. Ltd., Anterogen. Co. Ltd., Pharmicell Inc., NuVasive Inc., RTI Surgical Ltd., JCR Pharmaceuticals Co. Ltd., Holostem Terapie Avanzate Srl, Regrow Biosciences Pvt Ltd., Stempeutics Research Pvt Ltd., 3D Biomatrix, Worthington Biochemical
Get The Full Global Hematopoietic Stem Cell Transplantation Market Report
Hematopoietic Stem Cell Transplantation Market Overview
Hematopoietic stem cell transplantation (HSCT) refers to the process of a medical procedure that is used to treat various blood and bone marrow disorders, such as certain genetic disorders and autoimmune diseases. The procedure involves replacing a patient's damaged or diseased bone marrow with healthy stem cells from a donor, which then grow and produce new blood cells in the patient's body. These stem cells can be obtained from bone marrow, peripheral blood, or umbilical cord blood.
Hematopoietic Stem Cell Transplantation Global Market Report 2023 provides data on the global hematopoietic stem cell transplantation market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The hematopoietic stem cell transplantation market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.